Status:
UNKNOWN
Mesenchymal Stem Cells Transplantation for Ischemic-type Biliary Lesions
Lead Sponsor:
Yang Yang
Conditions:
Ischemic-type Biliary Lesions
Eligibility:
All Genders
18-60 years
Phase:
PHASE2
PHASE3
Brief Summary
Ischemic-type biliary lesions (ITBLs) are a major cause of graft loss and mortality after orthotopic liver transplantation (OLT). For now, there are still lacking effective treatment for ITBLs. The pu...
Detailed Description
Advances in organ preservation techniques, immunosuppressive regimens, and surgical techniques have resulted in reduced rates of infection, acute rejection and vascular complications after orthotopic ...
Eligibility Criteria
Inclusion
- benign end-stage liver disease patients with liver transplantation.
- ages of 18 and 60 years.
- first liver transplant.
- gamma-glutamyltransferase \> 300 U/L for 2 weeks, and there was no or low enhancement of the wall of the hilar bile duct in arterial phase via contrast-enhanced ultrasonography.
- Written informed consent.
Exclusion
- second or combined organ transplant recipient.
- vital organs failure (Cardiac, Renal or Respiratory, et al).
- clinically active bacterial, fungal, viral or parasitic infection.
- other candidates who are judged to be not applicable to this study by investigators.
Key Trial Info
Start Date :
July 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2018
Estimated Enrollment :
66 Patients enrolled
Trial Details
Trial ID
NCT02223897
Start Date
July 1 2014
End Date
June 1 2018
Last Update
August 22 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Third Affiliated Hospital, Sun Yat-Sen University
Guangzhou, Guangdong, China, 510630